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Autism spectrum disorders (ASD) are multifactorial 
conditions, with obvious genetic, epigenetic and/or 
environmental risk factors implicated in the disease 
etiology. Identification of several gene mutations in 
human ASD and rodent models carrying mutations in the 
same candidate genes recapitulating the behavioral core 
symptoms of ASD -namely lack of social interaction, 
impaired communication and repetitive, stereotyped 
behaviors -helped to test hypotheses on the etiology of 
ASD. Discomfortingly, single gene defects account only 
for 1% of ASD cases [1]; thus the search of convergent 
pathways aimed to “reduce ASD complexity” might 
help to develop therapies to treat ASD. In recent years, 
a subpopulation of inhibitory (GABAergic) interneurons 
(hereafter termed Pvalb neurons) expressing the calcium-
binding protein parvalbumin (PV) has gained increased 
attention with respect to ASD. Pvalb neurons play a 
key role in the coordination of neuronal networks and 
associated oscillations. Studies in ASD animal models 
[2] revealed the number of PV-immunoreactive (PV+) 
cells to be decreased, and such a decrease was also 
observed in post mortem brains of ASD patients [3]. The 
decrease of PV+ neurons was (implicitly or explicitly) 
assumed to be the result of partial loss of the Pvalb 
neurons (Figure 1). Since also mice with reduced (PV+/-) 
or absent (PV-/-) PV expression levels show behavioral 
deficits relevant to human ASD core symptoms [4], the 
question arose, whether the reduction in the number of 
PV+ neurons was the result of Pvalb neuron loss and/
or a decrease in PV expression. From a viewpoint 
of PV immunohistochemistry, the two possibilities 
are indistinguishable, requiring a second marker for 
the identification of Pvalb neurons: e.g. Vicia Villosa 
Agglutinin (VVA), a lectin binding to specific extracellular 
matrix components forming a net-like structure around 
Pvalb neurons (Figure 1). The number of PV+ or VVA-
positive (VVA+) neurons was counted in three ASD-
associated brain regions: medial prefrontal cortex, 
somatosensory cortex and striatum. Results in all three 
regions were identical: the unchanged number of VVA+ 
cells in PV+/- and PV-/- mice demonstrated that Pvalb 
neurons are still present and that the lower number of PV+ 
neurons (in PV+/- mice) or the absence of PV+ cells (in 
PV-/- mice) is the result of diminished/absent expression 
of PV in these interneurons [5]. Since the PVALB gene 
is not considered as a bona fide ASD risk gene (as it has 
never been identified in genetic screens), we analyzed 
knockout mouse models of two well-accepted ASD risk 
genes: Shank1 and Shank3. Mutations in SHANK genes 
are considered as highly relevant factors for ASD. In both, 
Shank1-/- and Shank3B-/- mice, we observed a decrease 
in PV+ neurons in the SSC and striatum, respectively, 
resulting from decreased Pvalb mRNA and PV protein, 
yet without any significant changes in the number of Pvalb 
neurons. Most recently, Pvalb neurons were investigated 
in a widely recognized environmental ASD mouse model 
[2], i.e. in mice exposed in utero to valproic acid (VPA). 
Again the number of Pvalb neurons was unaltered, while 
the observed lower number of PV+ neurons in the striatum 
(-15%) was due to a decrease in Pvalb mRNA (-50%) and 
PV protein (-30%) [6]. Taken together, the down-regulation 
of PV in genetic (Shank1-/-, Shank3B-/-, PV+/-) and 
environmental (VPA) mouse ASD models, and moreover 
in specific brain regions provides a common link between 
seemingly unrelated defects causing ASD. The origin of 
the reported decrease in the number of PV+ neurons in 
human ASD brains [3], as well as in other mouse ASD 
models reported before [4] remains an open, however 
highly pertinent question. Although it is unquestionable 
that alterations of the Pvalb-neuron circuitry profoundly 
affect neuronal networks, ultimately resulting in/
contributing to the so-called excitation/inhibition 
imbalance in ASD, we consider it an absolute necessity 
to unequivocally distinguish between Pvalb neuron loss 
or reduction of PV protein levels. In the first place, this 
likely leads to a more substantiated interpretation of the 
previously reported physiological changes in mouse ASD 
models with lower PV+ neuron numbers. Evidently, loss 
Figure 1: A. Pvalb neurons targeting pyramidal cells (blue) 
and other Pvalb neurons generally identified by the presence 
of PV (red) are surrounded by perineuronal nets (PNN; green). 
B. PV down-regulation or loss/absence of Pvalb interneurons 
is indistinguishable on brain sections immunostained with a 
parvalbumin antibody only.
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of Pvalb neurons leads to diminished inhibition, whereas 
PV down-regulation increases short-term facilitation and 
thus “enhances” inhibition [for review see 7]. Second, 
if PV down-regulation, not Pvalb neuron loss, would 
be confirmed in other ASD models with reported lower 
numbers of PV+ neurons, then a diminution in PV and the 
physiological changes associated with it might represent 
a common convergent pathway, possibly resulting in the 
core ASD phenotype despite different initial causes, e.g. 
as a downstream consequence of mutations in ASD risk 
genes. This in turn might reveal PV as an emerging new 
target, in particular when proven that PV upregulation 
might rescue, or at least diminish, the ASD behavioral 
phenotype.
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